You are here

  • Home
  • Archive
  • Volume 10, Issue 7
  • T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine

Article info

Article menu
Case report
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine

Authors

  • Djordje Atanackovic Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA Department of Microbiology and Immunology, University of Maryland Baltimore, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Robert J Kreitman National Cancer Institute, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Jeffrey Cohen NIAID, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Nancy M Hardy Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Destiny Omili Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Thierry Iraguha Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Peter D Burbelo NIDCR, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Etse Gebru Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Xiaoxuan Fan University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • John Baddley University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA Institute of Human Virology, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Tim Luetkens University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA Department of Microbiology and Immunology, University of Maryland Baltimore, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Saurabh Dahiya Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Aaron P Rapoport Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Djordje Atanackovic; datanackovic{at}som.umaryland.edu
View Full Text

Citation

Atanackovic D, Kreitman RJ, Cohen J, et al
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine
Journal for ImmunoTherapy of Cancer 2022;10:e004953. doi: 10.1136/jitc-2022-004953

Publication history

  • Accepted May 20, 2022
  • First published July 17, 2022.
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.